{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:25:44Z","timestamp":1777685144060,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2019,10,24]]},"DOI":"10.3233\/jhd-190354","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T10:56:32Z","timestamp":1566557792000},"page":"483-492","source":"Crossref","is-referenced-by-count":5,"title":["Impaired Isometric Force Matching in Upper and Lower Limbs Revealed by Quantitative Motor Assessments in Huntington\u2019s Disease"],"prefix":"10.1177","volume":"8","author":[{"given":"Sabrina","family":"Medzech","sequence":"first","affiliation":[{"name":"George-Huntington-Institute, Deilmann-Building IV, Technology-Park, Muenster, Germany"},{"name":"Department of Neurology, University of Muenster, Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sass","sequence":"additional","affiliation":[{"name":"George-Huntington-Institute, Deilmann-Building IV, Technology-Park, Muenster, Germany"},{"name":"Department of Neurology, Asklepios Klinikum Harburg, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Bohlen","sequence":"additional","affiliation":[{"name":"George-Huntington-Institute, Deilmann-Building IV, Technology-Park, Muenster, Germany"},{"name":"Institute for Clinical Radiology, University of Muenster, Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herwig W.","family":"Lange","sequence":"additional","affiliation":[{"name":"George-Huntington-Institute, Deilmann-Building IV, Technology-Park, Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Koch","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of Muenster, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Schubert","sequence":"additional","affiliation":[{"name":"George-Huntington-Institute, Deilmann-Building IV, Technology-Park, Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Bernd","family":"Ringelstein","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Muenster, Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Reilmann","sequence":"additional","affiliation":[{"name":"George-Huntington-Institute, Deilmann-Building IV, Technology-Park, Muenster, Germany"},{"name":"Institute for Clinical Radiology, University of Muenster, Muenster, Germany"},{"name":"Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"9557","key":"10.3233\/JHD-190354_ref1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.3233\/JHD-190354_ref2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/mds.26012","article-title":"Determinants of functional disability in Huntington\u2019s disease: Role of cognitive and motor dysfunction","volume":"29","author":"Ross","year":"2014","journal-title":"Mov Disord"},{"issue":"7","key":"10.3233\/JHD-190354_ref3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: Analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JHD-190354_ref4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.parkreldis.2018.01.006","article-title":"The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington\u2019s disease","volume":"49","author":"Zielonka","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"10.3233\/JHD-190354_ref5","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/mds.23816","article-title":"Assessment of involuntary choreatic movements in Huntington\u2019s disease\u2014 toward objective and quantitative measures","volume":"26","author":"Reilmann","year":"2011","journal-title":"Mov Disord"},{"issue":"11","key":"10.3233\/JHD-190354_ref6","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.25996","article-title":"Chorea associated with Huntington\u2019s disease: To treat or not to treat?","volume":"29","author":"Jankovic","year":"2014","journal-title":"Mov Disord"},{"issue":"16","key":"10.3233\/JHD-190354_ref7","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/mds.23300","article-title":"Grasping premanifest Huntington\u2019s disease - shaping new endpoints for new trials","volume":"25","author":"Reilmann","year":"2010","journal-title":"Mov Disord"},{"issue":"3","key":"10.3233\/JHD-190354_ref8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-190354_ref9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.3233\/JHD-190354_ref10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","article-title":"Pharmacological treatment of chorea in Huntington\u2019s disease-good clinical practice versus evidence-based guideline","volume":"28","author":"Reilmann","year":"2013","journal-title":"Mov Disord"},{"issue":"11","key":"10.3233\/JHD-190354_ref11","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/mds.26014","article-title":"Current therapeutic options for Huntington\u2019s disease: Good clinical practice versus evidence-based approaches?","volume":"29","author":"Killoran","year":"2014","journal-title":"Mov Disord"},{"issue":"Suppl.1","key":"10.3233\/JHD-190354_ref12","first-page":"568","article-title":"Design of the LEGATO-HD study: A multinational, randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of laquinimod (0.5, 1.0 and 1.5mg\/day) as treatment in patients with Huntington\u2019s disease","volume":"30","author":"Reilmann","year":"2015","journal-title":"Mov Disord"},{"issue":"7","key":"10.3233\/JHD-190354_ref13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/mds.27363","article-title":"Huntington\u2019s disease: Current and future therapeutic prospects","volume":"33","author":"Kieburtz","year":"2018","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-190354_ref14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington\u2019s Disease Rating Scale: Reliability and consistency","volume":"11","author":"Huntington Study Group","year":"1996","journal-title":"Mov Disord"},{"issue":"3","key":"10.3233\/JHD-190354_ref15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/mds.20332","article-title":"Interrater agreement in the assessment of motor manifestations of Huntington\u2019s disease","volume":"20","author":"Hogarth","year":"2005","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-190354_ref16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/B978-0-12-801893-4.00018-3","article-title":"Motor outcome measures in Huntington disease clinical trials","volume":"144","author":"Reilmann","year":"2017","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"10.3233\/JHD-190354_ref17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.26174","article-title":"A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington\u2019s disease","volume":"30","author":"Reilmann","year":"2015","journal-title":"Mov Disord"},{"issue":"Suppl. 1","key":"10.3233\/JHD-190354_ref18","first-page":"A99","article-title":"A randomized, double-blind, placebo-controlled phase II efficacy and safety study of the pde10a inhibitor PF-02545920 in Huntington disease (AMARYLLIS)","volume":"89","author":"Delnomdedieu","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"13","key":"10.3233\/JHD-190354_ref19","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/mds.23243","article-title":"Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington\u2019s disease","volume":"25","author":"Reilmann","year":"2010","journal-title":"Mov Disord"},{"issue":"3","key":"10.3233\/JHD-190354_ref20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hbm.21449","article-title":"Clinical impairment in premanifest and early Huntington\u2019s disease is associated with regionally specific atrophy","volume":"34","author":"Scahill","year":"2013","journal-title":"Hum Brain Mapp"},{"key":"10.3233\/JHD-190354_ref21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12883-015-0451-9","article-title":"Deficits in tongue motor control are linked to microstructural brain damage in multiple sclerosis: A pilot study","volume":"15","author":"Holtbernd","year":"2015","journal-title":"BMC Neurol"},{"issue":"9","key":"10.3233\/JHD-190354_ref22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.3233\/JHD-190354_ref23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: Analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.3233\/JHD-190354_ref24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7348","article-title":"Coordination of prehensile forces during precision grip in Huntington\u2019s disease","volume":"163","author":"Gordon","year":"2000","journal-title":"Exp Neurol"},{"issue":"5","key":"10.3233\/JHD-190354_ref25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.57.5.920","article-title":"Objective assessment of progression in Huntington\u2019s disease: A 3-year follow-up study","volume":"57","author":"Reilmann","year":"2001","journal-title":"Neurology"},{"issue":"24","key":"10.3233\/JHD-190354_ref26","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1212\/WNL.0b013e3182020123","article-title":"Tapping linked to function and structure in premanifest and symptomatic Huntington disease","volume":"75","author":"Bechtel","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/JHD-190354_ref27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/mds.24908","article-title":"Huntington\u2019s disease: Objective assessment of posture\u2014 a link between motor and functional deficits","volume":"27","author":"Reilmann","year":"2012","journal-title":"Mov Disord"},{"issue":"8","key":"10.3233\/JHD-190354_ref28","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/mds.21987","article-title":"Spectrum of gait impairments in presymptomatic and symptomatic Huntington\u2019s disease","volume":"23","author":"Rao","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-190354_ref29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.gaitpost.2018.03.039","article-title":"Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study","volume":"62","author":"Beckmann","year":"2018","journal-title":"Gait Posture"},{"issue":"7","key":"10.3233\/JHD-190354_ref30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/mds.22003","article-title":"Falls and gait disturbances in Huntington\u2019s disease","volume":"23","author":"Grimbergen","year":"2008","journal-title":"Mov Disord"},{"issue":"5","key":"10.3233\/JHD-190354_ref31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ana.410410521","article-title":"CAG repeat number governs the development rate of pathology in Huntington\u2019s disease","volume":"41","author":"Penney","year":"1997","journal-title":"Ann Neurol"},{"key":"10.3233\/JHD-190354_ref32","volume-title":"Brain and Behavior in Human Development","author":"Gordon","year":"2001"},{"issue":"1","key":"10.3233\/JHD-190354_ref33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1388-2457(00)00497-1","article-title":"Deficits in sensorimotor control during precise hand movements in Huntington\u2019s disease","volume":"112","author":"Schwarz","year":"2001","journal-title":"Clin Neurophysiol"},{"issue":"6769","key":"10.3233\/JHD-190354_ref34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/35000576","article-title":"Motor disorder in Huntington\u2019s disease begins as a dysfunction in error feedback control","volume":"403","author":"Smith","year":"2000","journal-title":"Nature"},{"issue":"8","key":"10.3233\/JHD-190354_ref35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/mds.20482","article-title":"Reliability of spatiotemporal gait outcome measures in Huntington\u2019s disease","volume":"20","author":"Rao","year":"2005","journal-title":"Mov Disord"},{"issue":"3","key":"10.3233\/JHD-190354_ref36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/mdc3.12618","article-title":"Interrater reliability of the Unified Huntington\u2019s Disease Rating Scale-total motor score certification","volume":"5","author":"Winder","year":"2018","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"10.3233\/JHD-190354_ref37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): A phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-190354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:50:53Z","timestamp":1777452653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-190354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":37,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jhd-190354","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]}}}